Home/Pipeline/CDMO - Client Molecule A

CDMO - Client Molecule A

Oncology

Phase IIIActiveConfidential

Key Facts

Indication

Oncology

Phase

Phase III

Status

Active

Company

Gland Pharma

About Gland Pharma

Gland Pharma's mission is to be a leading global provider of high-quality, affordable injectable medicines. The company has achieved this through a combination of deep expertise in complex sterile manufacturing, strategic partnerships like the one with Fosun Pharma, and a successful IPO in 2020. Its core strategy focuses on expanding its CDMO business, leveraging its R&D for differentiated formulations, and penetrating new regulated and emerging markets to drive sustainable growth.

View full company profile

Therapeutic Areas

Anti-infectives Cardiology Critical Care Oncology Nephrology Anesthesia

Other Oncology Drugs

Drug	Company	Phase	Status
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active
Personalized Medicine Assays (Patient-Derived Explants)	Aurita Bioscience	Research-Use Only	Active
CDK2-CyclinE1 & CDK2-CyclinA2 Assay	Aurora Biolabs	Commercial	Available
POLQ & eIF4E Assay	Aurora Biolabs	Commercial	Available
PKMYT1 & WEE1 Assay	Aurora Biolabs	Commercial	Available
NTP42	ATXA Therapeutics	Preclinical	Efficacy validated in preclinical models
Athebody® DARPins for pHLA-binding T-Cell Engagers	Athebio	Pre-clinical	Platform Application
Dual-Targeting CAR-T Programs	Factor Bioscience	Pre-clinical	Active